Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.8.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents [note 7] $ 4,165 $ 5,284
Restricted cash [note 7 and note 10] 222 222
Amounts receivable 7 9
Prepaid expenses 352 393
Total current assets 4,746 5,908
Restricted cash [note 7] 50 50
Property and equipment, net 18 59
Other assets 135 309
License agreement [note 2, 4, 5 and 6] 2,477 2,532
Goodwill [note 2 and 5] 1,034 1,034
Total assets 8,460 9,892
Current liabilities:    
Accounts payable 420 213
Accrued liabilities other 532 438
Accrued clinical liabilities 774 877
Accrued compensation 592 458
Current portion of long-term obligations [note 10]   27
Total current liabilities 2,318 2,013
Total liabilities 2,318 2,013
Commitments and contingencies [note 10]
Stockholders' equity:    
Common stock, $0.001 par value, 75,000,000 shares authorized, 12,756,752 and 11,956,752 issued at March 31, 2018 and December 31, 2017, respectively, and 12,747,932 and 11,947,932 outstanding at March 31, 2018 and December 31, 2017, respectively 13 12
Additional paid-in capital 21,840 20,556
Accumulated deficit (15,716) (12,694)
Accumulated other comprehensive income 5 5
Total stockholders' equity 6,142 7,879
Total liabilities and stockholders' equity $ 8,460 $ 9,892